James Vardiman to Antineoplastic Agents
This is a "connection" page, showing publications James Vardiman has written about Antineoplastic Agents.
Connection Strength
0.439
-
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun. 2018 03 21; 9(1):1163.
Score: 0.274
-
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
Score: 0.127
-
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
Score: 0.013
-
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004 Feb; 124(3):275-88.
Score: 0.006
-
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 2003 Feb; 17(2):323-7.
Score: 0.006
-
Histiocytic lymphoma: response to chemotherapy. Ann Intern Med. 1982 Oct; 97(4):617-8.
Score: 0.006
-
Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood. 1992 Nov 15; 80(10):2463-70.
Score: 0.003
-
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood. 1987 Mar; 69(3):872-7.
Score: 0.002
-
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986 Mar; 4(3):325-45.
Score: 0.002